CURRENT AFFAIRS | 29 MAY 2026
A landmark study published in The Lancet, led by Professor Kristine Yaffe of the University of California San Francisco (UCSF), has shown that a simple blood test measuring three biomarkers — Aβ42, Aβ40 and p-tau217 — can flag Alzheimer’s pathology in cognitively-normal adults years before symptoms appear. The implications for screening, disability law, and contractual capacity jurisprudence are considerable.
What the Numbers Showed
Among 1,350 dementia-free adults (average age 61) tracked for five years, 6% (~86 participants) had elevated tau and amyloid at baseline. These individuals later showed 2.5–4× faster decline in verbal memory and 3–4× higher risk of processing-speed loss compared to peers. The finding confirms Alzheimer’s pathology begins years before clinical symptoms.
Why This Matters Beyond Medicine
Mumbai neurologist Anil Venkitachalam notes the test “may help differentiate Alzheimer’s from other dementias” — vital because India houses an estimated 5.3 million people with dementia (2025 Indian Journal of Public Health), 60–70% of whom likely have Alzheimer’s. New anti-amyloid drugs (Lecanemab, Donanemab) are in the DCGI approval pipeline.
Constitutional & Legal Framework
- Mental Healthcare Act 2017 — implements UNCRPD obligations
- Rights of Persons with Disabilities Act 2016 — Schedule lists dementia
- Maintenance & Welfare of Parents and Senior Citizens Act 2007
- National Policy on Senior Citizens 2011
- Section 12, Indian Contract Act 1872 — capacity / sound mind
- Article 21 — right to health (Paschim Banga Khet Mazdoor Samiti v WB, 1996)
Why This Matters for CLAT 2027
Health-tech advances tie into capacity-to-contract questions (Section 12 ICA), drug-patent jurisprudence (Novartis v UoI, 2013), DCGI regulatory architecture, and the RPWD 2016 disability schedule. Expect a current-affairs item linking the Lancet finding to either Mental Healthcare Act 2017 or the new anti-amyloid drug approvals.
Key Facts
| Study | UCSF, published in The Lancet |
| Biomarkers | Aβ42, Aβ40, p-tau217 |
| Cohort | 1,350 adults, avg age 61 |
| Indians with dementia | 5.3 mn (IJPH 2025) |
| Senior author | Prof. Kristine Yaffe |
Mnemonic — T-A-P
Tau (p-tau217) · Amyloid (Aβ42/Aβ40) · Proactive screening 5 years early.
Test Your Understanding
Practice Quiz — 10 CLAT-Style Questions
Click an option to reveal the answer and explanation.
